TRINETRA › Sectors › Healthcare
Cipla Limited (CIPLA) — share price, P/E and fundamentals
Cipla Limited (NSE: CIPLA) closed at ₹1,378.90 on 30 Oct 2026, -12.6% over one year, against a 52-week range of ₹1,165.70 – ₹1,673.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 27 Oct 2026) it reported revenue of ₹7,404 cr and net profit of ₹878 cr, a 11.9% net margin; revenue fell 2.4% and profit fell 36.5% year on year.
On four consecutive filed quarters its trailing P/E is 38.5; since 13 May 2025 its own P/E has ranged from 21.0 to 38.4 (median 23.6), and today's reading is higher than 100% of those 363 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 9.9%, ROCE 13.1%, debt-to-equity 0.01, Piotroski F-score 4 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 40% of 63 sector peers; PBT margin higher than 38% of 63 sector peers; ROE higher than 25% of 63 sector peers.
Key figures
| Last close | ₹1,378.90 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -1.4% / +6.5% / -12.6% |
| 52-week low – high | ₹1,165.70 – ₹1,673.00 |
| Market capitalisation | ₹1,11,394 cr |
| Trailing P/E | 38.5 |
| Price / book | 3.15 |
| EV / EBITDA | 21.0 |
| Earnings yield | 2.6% |
| TTM EPS | ₹35.86 |
| TTM net profit | ₹2,897 cr |
| Quarter revenue | ₹7,404 cr |
| Quarter net profit | ₹878 cr |
| Net margin | 11.9% |
| Revenue growth (YoY) | -2.4% |
| Profit growth (YoY) | -36.5% |
| Return on equity | 9.9% |
| ROCE | 13.1% |
| Debt / equity | 0.01 |
| Current ratio | 3.59 |
| Free cash flow | ₹302 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹113.6 cr |
Against Healthcare peers
| Metric | CIPLA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 11.85 | 12.89 | 40 |
| PBT margin | 15.90 | 17.68 | 38 |
| ROE | 9.92 | 13.87 | 25 |
| ROCE | 13.10 | 17.26 | 27 |
| Debt / equity | 0.01 | 0.11 | 28 |
| FCF margin | 2.08 | -0.87 | 57 |
| Cash conversion | 0.74 | 1.25 | 15 |
| Trailing P/E | 38.45 | 43.26 | 39 |
Questions
What is the P/E ratio of Cipla Limited?
Cipla Limited's trailing P/E is 38.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 13 May 2025 its P/E has ranged 21.0–38.4.
What were Cipla Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Cipla Limited reported revenue of ₹7,404 cr and net profit of ₹878 cr (consolidated), filed with the exchange on 27 Oct 2026.
What is Cipla Limited's ROE?
Return on equity is 9.9% based on the balance sheet dated 30 Sept 2026.
Does Cipla Limited have debt?
Debt-to-equity is 0.01 on the balance sheet dated 30 Sept 2026.
What is CIPLA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, CIPLA traded between ₹1,165.70 and ₹1,673.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.